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In everyday psychiatric practice, di-
agnoses are made by noting the constel-
lation of a patient’s symptoms, with little 
contribution from observable signs and 
virtually none from investigations. This 
places psychiatry in an unusual, but 
not unique, position compared to other 
medical disciplines (1,2). Diagnostic 
accuracy, prognostication, management 
plans, and treatment evaluation are 
dependent on relatively subjective cli-
nician assessments, and thereby prey 
to undue cultural influences and value 
judgements (3,4). There is a pressing 
need for objective tests to improve the 
classification of psychiatric disorders, to 
stratify patients into more homogeneous 
groups, and to plan their treatment ac-
cordingly. The current research focus 
on genetic, protein-based and imaging-
linked “biomarkers” could help move 
from syndromal diagnoses to an etio-
logical and/or pathophysiological clas-
sification, as well as aiding research into 
the identification of therapeutic targets. 
In the 100 years or so since schizo-
phrenia was first described (5) and 
named (6), the diagnostic criteria may 
have been refined, but the process in 
everyday practice has remained essen-
tially the same. Psychiatrists rely on the 
patient’s description of symptoms, men-
tal state examinations and behavioural 
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observations, in line with the categories 
listed in the DSM-IV and the ICD-10. 
In both manuals, the presence of one of 
Schneider’s first rank symptoms (FRS) is 
usually sufficient to make a diagnosis of 
schizophrenia. These diagnostic criteria 
have facilitated research into the causes 
of schizophrenia, and definite advances 
in our understanding of its origins and 
development have been realized. Several 
risk factors for the subsequent develop-
ment of schizophrenia are established 
beyond reasonable doubt (7,8), and an 
impressive array of genetic, anatomical, 
functional, neurophysiological and neu-
ropsychological findings regarding the 
pathophysiology of schizophrenia are 
now well replicated (9,10). The key clin-
ical question is, however, whether we 
have learned anything about the nature 
of schizophrenia that could be useful in 
the management of our patients. 
In this review, we address this ques-
tion in terms of making a diagnosis or 
an early diagnosis and in predicting 
therapeutic response. We do this by 
identifying the most robust findings and 
discussing their potential applications 
in clinical practice, in the realms of 
clinical features, historical information, 
cognitive testing, serum biomarkers, 
structural and functional imaging, and 
electrophysiological indices. 
MethoDs of the review
As we are interested here in clinical 
utility over and above statistical signifi-
cance, we concentrate on studies which 
provide data in terms of the sensitiv-
ity and specificity of the variables as a 
diagnostic aid, the predictive power of 
a test result and/or the likelihood that 
a test result in an individual patient is 
indicative of schizophrenia. It is worth 
noting that sensitivity and specificity are 
generally constant properties of a test, 
which are useful in service planning but 
not in dealing with individual patients. 
The positive predictive value (PPV) or 
negative predictive value (NPV) of a test 
result gives the risk level for a particu-
lar patient, which is useful clinically, but 
PPVs and NPVs are prevalence-depen-
dent measures, and performance can 
therefore vary markedly in different set-
tings (11). Likelihood ratios are a means 
of using sensitivity and specificity data 
to calculate the implications of test re-
sults in a particular patient (12-14). As a 
rough rule of thumb, likelihood ratios of 
a positive test result (LR+) of more than 
5, and preferably more than 10, increase 
the risk of disorder by about 30% or 
45%, respectively. The latter would, for 
example, indicate a clear change from a 
pre-test probability of say 50% (maximal 
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uncertainty) to a post-test probability of 
95% (highly likely). This might at first 
appear to be an alien practice, but it is 
for example what underpins the use of 
the CAGE questionnaire in identifying 
alcohol problems and the Mini Mental 
State Examination in diagnosing de-
mentia (15,16).
The type of study we need for a diag-
nostic test is a cross-sectional one com-
paring a representative population of pa-
tients and non-cases (controls for diagno-
sis, other diagnoses for differential diag-
nosis) who have been evaluated with the 
gold standard and blindly assessed with 
the test. For early diagnosis and treatment 
response tests, we need a longitudinal 
and preferably prospective study of a co-
hort of patients evaluated before or after 
the onset of their condition and followed 
up until outcome is clear, with preferably 
less than 20% loss to follow-up. 
In this review, we sought to identify 
replicated evidence from systematic re-
views for the diagnosis, early diagnosis 
and treatment response of schizophre-
nia, in terms of the reliability of the 
examination, the size of the difference 
between schizophrenia and controls, 
and the ability to discriminate versus bi-
polar disorder. In each of our specified 
domains, we particularly sought reviews 
with some consideration of measure-
ment reliability, heterogeneity and pub-
lication bias. We favoured reviews re-
porting an effect size such as Cohen’s d 
of 1 or more, as this roughly and gener-
ally corresponds to a 70% non-overlap 
of data distributions and an odds ratio 
(OR) of approximately 5 (17). 
DiAGNosis
In everyday medical practice, history-
taking identifies diagnostic “hypoth-
eses”. Evidence for and against these 
is sought on physical examination and 
(ideally) confirmatory diagnostic testing. 
In psychiatry, a similar initial approach 
is followed by the mental state exami-
nation, which includes more explicit 
evaluation of appearance, behaviour 
and speech than in the rest of medi-
cine, but also several questions that are 
just further history gathering and some 
cognitive testing often of dubious valid-
ity. We psychiatrists are curiously averse 
to physically examining our patients 
and surprisingly willing to accept “CNS 
grossly normal” in medical records when 
this probably means that no neurologi-
cal exam has been attempted. We might 
consider possible “organic” explana-
tions for “secondary schizophrenia” and 
contemplate referral for brain imaging in 
unusual cases, but that is about as far as 
investigation is usually taken. 
To provide some clinical background, 
and as a comparator for laboratory tests, 
we first consider the evidence base for 
key aspects of the clinical examination 
in making a diagnosis of schizophrenia. 
Clinical history and examination
Psychotic symptoms
Although counter-intuitive, and de-
spite the potential tautology, particular 
psychotic symptom types are not in 
themselves strong associates of schizo-
phrenia. Bizarre delusions, for example, 
are less reliably elicited (mean kappa 
across studies 0.5 or “moderate”) than 
delusions in general (0.7 or “substantial 
agreement”) (18), and have a low speci-
ficity, despite a PPV as high as 0.82 in 
214 consecutive admissions (19). Simi-
larly, Schneider’s FRS have been over-
sold as pathognomic, as they are both 
too rare to be a generally useful diag-
nostic aid, especially if strictly defined, 
and too common in other psychotic 
disorders (20). Peralta and Cuesta (21) 
recruited 660 inpatients with “the full 
spectrum” of psychotic disorders and 
found that any individual FRS usually 
had a LR+ of 1-2 for schizophrenia, de-
pending on the particular symptom and 
the diagnostic criteria examined, and no 
FRS had a LR+ more than 4. 
Risk factors as diagnostic aids
There is clear evidence that several 
variables increase the risk for schizo-
phrenia to a statistically significant de-
gree (7,8,22). Table 1 lists some of these. 
Indeed, many of these risk factors, and 
especially family and developmental his-
tory, are sometimes used as supportive 
evidence to make a diagnosis of schizo-
phrenia, but in an informal and variable 
way. These factors rarely elevate the risk 
by more than 5x relative to the baseline 
population risk of approximately 1%. 
Even elevating that risk to approximate-
ly 10% in the presence of a positive fam-
ily history in a first-degree relative (10) 
is clearly not very helpful, and reliably 
eliciting the information might require 
structured assessments (23). 
Where the presence of such risk fac-
tors might be helpful is in differential di-
agnosis, perhaps particularly in hospital 
settings where psychosis is much more 
prevalent, as the major psychoses may 
breed partially true (24), and urban birth 
and developmental disruption may be 
more potent risks for schizophrenia 
than bipolar disorder (22). 
On the other hand, although the risk of 
schizophrenia is clearly elevated by expe-
riencing obstetric complications (OCs), 
the additional risk from any one com-
plication is much smaller, and OCs pro- 
bably increase the odds of a range of 
adverse neurodevelopmental outcomes 
(25,26). If one was to make clinical use 
of the association between immigration 
and schizophrenia, despite the hetero-
geneity (27), one might quickly run into 
allegations of racism. Regular canna-
bis use is a risk factor for schizophre-
nia (28,29), but it is sometimes argued, 
Table 1  Best replicated historical risk factors for schizophrenia (adapted from 7,22)
Variable Level of risk Key supporting reference
Family history
Immigrant status
Childhood social difficulties
Obstetric complications
Cannabis use
RR up to 50
OR = 5
OR up to 5
OR = 2-3
OR = 2-3
Gottesman (10)
Cantor-Graae and Selten (27)
Tarbox and Pogue-Geile (110)
Cannon et al (26)
Moore et al (29)
RR – risk ratio; OR – odds ratio
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without much evidence, that this may 
not be a causal relationship, i.e. that 
people with pre-schizophrenia take up 
cannabis use perhaps in a bid to self-
medicate (30). Nevertheless, it is clear 
from randomized controlled trials that 
cannabinoids prescribed, for example, 
as anti-emetics for people with cancer 
increase the risk of hallucinations about 
six-fold and delusions more than eight-
fold (31). Cannabis may therefore only 
induce psychotic symptoms, and some 
additional factor or at least chronic, fre-
quent use may be required before schizo-
phrenia develops. Thus, the standard 
clinical practice of making a diagnosis 
of drug or cannabis induced psychosis 
in regular drug users, and watchful wait-
ing to see if schizophrenia develops, is 
probably rational. We are not aware, 
however, of any studies examining this 
practice, or indeed the relative merits of 
subjective versus objective assessments 
of cannabis use in so doing. 
It should hopefully be clear that we 
do use risk factors in making a diagnosis 
of schizophrenia, but as currently imple-
mented this is haphazard.
Physical signs 
Despite our reluctance to examine 
our patients physically, it is clear that 
there are some physical signs which are 
risk factors for schizophrenia and of po-
tential pathophysiological significance. 
Minor physical “anomalies” like abnor-
mal head circumference, hypertelorism, 
and non-right handedness are, however, 
too non-specific and only raise the risk 
of schizophrenia slightly (32,33), while 
dermatoglyphic patterns are difficult 
to discern (34). Neurological “soft” 
signs (NSS) are more promising, as it 
has been reported that 50-60% of pa-
tients with schizophrenia have observ-
able deficits in sensory integration and 
motor coordination, as compared to 
about 5% of normal controls (35). In a 
thorough recent systematic review and 
meta-analysis, Chan et al (36) found an 
overall effect size of 1.08, corresponding 
to a 73% separation (17) between the 
populations, although this effect size is 
probably inflated by the difficulties in 
blinding such assessments to patient 
and control status. There was, however, 
largely unexplained statistical heteroge-
neity, and evidence of publication bias, 
potentially attributable to difficulties 
in reliably eliciting these appropriately 
named phenomena. 
Rigorous evaluation of NSS may be 
particularly difficult in patients with the 
most acute psychoses. Further, while it 
is clear that these signs are not simply 
attributable to antipsychotic treatment, 
it is unclear to what extent they reflect 
the nature of the underlying pathophysi-
ological processes of schizophrenia, as 
disease specificity has only been stud-
ied rarely (35). Given, however, that 
certain NSS may be more genetically 
mediated (37), and that NSS have been 
proposed as clinical and functional out-
come predictors (35), the area does look 
promising for further clinically oriented 
research (see Table 2). There may be 
value in considering the reliability and 
diagnostic specificity of individual signs 
within the major domains of NSS and 
their likely anatomical underpinnings – 
motor dexterity (cerebellum), primitive 
reflexes (frontal lobe), motor sequencing 
(prefrontal cortex, PFC), and sensory in-
tegration (parietal lobe) – in more detail 
than just a global NSS score. 
Cognitive testing 
Examining cognitive status in every-
day psychiatric practice is usually done 
with a few quick tests of largely un-
proven reliability and validity. Evaluat-
ing cognitive performance rigorously is 
not routine outside a research setting, 
but patients with schizophrenia cer-
tainly have a range of intellectual im-
pairments (38), most of which are evi-
dent at first episode (39). Meta-analyses 
have identified large (d>1) deficits in 
general intelligence (38-40), processing 
speed (41), various aspects of memory 
(38,39,42,43), verbal fluency (44), social 
cognition (45) and theory of mind (46). 
It remains difficult, however, to estab-
lish whether there are specific deficits 
over and above general performance 
decrements. There is also marked het-
erogeneity between studies, potentially 
attributable to the effects of mental state 
on performance and cooperation, the 
fact that many patients can approach 
normal performances at times, as well 
as variation in the populations studied 
and in how assessments are conducted 
and scored. 
From a pathophysiological point of 
view, there is also the problem that 
many of these cognitive deficits appear 
to be largely present prior to the onset of 
psychosis, with some further deteriora-
tion, in some cases at least, after onset; 
all probably confounded by other risk 
Table 2  Large consistent effects from meta-analyses of studies of physical and cognitive examinations of patients with schizophrenia  
versus controls
Effect size 
vs. controls
Different from  
relatives
Evident at first  
episode
Specificity vs.  
bipolar disorder
Other issues
NSS 1.08, but with heterogeneity
(Chan et al, 36)
Yes Yes Requires more study Blinding reliability and 
practicality issues; specific 
domains and items may have 
stronger diagnostic properties
IQ 1.10, but with heterogeneity
(Heinrichs and Zakzanis, 38)
Yes Yes, at least in part,  
but some possible 
progression
Premorbid IQ deficits  
may differentiate
Various methods
NSS – neurological “soft” signs
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factors, treatment effects and other as-
pects of the disorder (40,47). Very few 
studies in this vast literature have con-
sidered the potential diagnostic utility 
of deficits, although there are replicat-
ed demonstrations that about 80% of 
patients score below normal memory 
thresholds (48,49). 
From a clinical perspective, most 
task deficits also appear to be evident 
in patients with bipolar disorder and 
psychotic depression, albeit to a slightly 
lesser extent (50-52). General intellec-
tual impairments are, however, more 
commonly found in schizophrenia than 
bipolar disorder, especially before diag-
nosis (38,51). It may be that IQ level, 
and perhaps especially pre- to post-
morbid deterioration, would provide 
useful information in making diagnoses 
(53,54), or perhaps in identifying a sub-
group at risk of poor prognosis and/or 
in need of aggressive treatment. Given 
the heterogeneity in IQ assessments in 
schizophrenia, it may also make sense 
to evaluate discrete aspects such as pro-
cessing speed or verbal fluency, perhaps 
as part of brief assessments with well-
evaluated psychometric properties, such 
as the Brief Assessment of Cognition in 
Schizophrenia (55).
Blood tests for “biomarkers”
Genomics
It is well known that schizophrenia 
has a large heritable component. Genet-
ic factors and gene-environment interac-
tions contribute up to 80% of the liability 
to the illness (10,56). As the clinical phe-
notype is complex, and the pathophysi-
ology is likely to be polygenic, the genes 
involved have been hard to find. In re-
cent years, a number of convergent find-
ings in linkage (57), association and ani-
mal studies have consistently implicated 
several genes, for which the most consis-
tent evidence is arguably for the “Icelan-
dic haplotype” in the neuregulin-1 gene 
(58), although the overall OR of about 2 
and continuing uncertainty about which 
particular genotype is implicated mean 
that this remains of purely research in-
terest. The recent complete mapping of 
the human genome has enabled several 
genome wide association studies in 
schizophrenia, which have been meta-
analysed to reveal multiple small effects 
across the genome, with the strongest 
overall effect (OR ~ 1.09) being in the 
ZNF804A gene encoding a putative zinc 
finger protein (59). 
Rare variants conferring risk for schizo- 
phrenia have also been identified. Per-
haps the most striking example is the 
DISC1 (Disrupted in Schizophrenia 1) 
gene, identified in a large Scottish family 
in which a chromosomal translocation 
is associated with a high frequency of 
schizophrenia (60), although this trans-
location is possibly unique to this family 
and raises the risk for bipolar disorder 
and depression as well. Smaller chro-
mosomal abnormalities, known as copy 
number variants (CNVs), are also more 
common in patients with schizophrenia 
than controls. One relatively common 
example is the 22q11 deletion known 
to occur in velo-cardio-facial syndrome, 
which is associated with a greatly in-
creased risk (RR ~ 30x). Notably, this 
genomic region includes the catechol-
O-methyltransferase (COMT) gene, in-
volved in dopamine metabolism, which 
may also be a risk gene for schizophrenia, 
perhaps especially in multiply affected 
families. Initial genome-wide studies of 
CNVs provide replicated associations of 
schizophrenia with rare 1q21.1, 15q11.2 
and 15q13.3 deletions. Collectively, sev- 
eral rare CNVs may elevate risk for 
schizophrenia, perhaps especially the 
more developmental forms of the disor-
der, but large CNVs do not appear to be 
implicated in bipolar disorder. Includ-
ing 22q11.2 deletions, CNVs appear to 
account for up to 2% of schizophrenia 
(61). It would however be premature 
to routinely screen patients for CNVs, 
both because causality has yet to be es-
tablished and the information gained 
might not influence management. 
Proteomics
Quantitative and qualitative protein 
patterns in cerebrospinal fluid (CSF) 
and serum have potential as diagnostic 
and prognostic biomarkers in schizo-
phrenia and other psychiatric disorders 
(62-64). There has been much interest 
in serum brain-derived neurotrophic 
factor (BDNF) levels in patients with 
schizophrenia, as BDNF has roles in 
neuronal proliferation, differentiation 
and dopamine neurotransmission, but 
extremely mixed results have been re-
ported compared with controls. Incon-
clusive results have also been reported 
for serum levels of epidermal growth 
factor. There are more consistent results 
from several studies supporting an as-
sociation between schizophrenia and 
S100B, a calcium-binding protein pro-
duced primarily by astrocytes, where 
increased concentrations likely result 
from astrocyte destruction. Most stud-
ies report increases in serum and CSF 
S100B concentrations in schizophrenia 
(65-68). 
The potential importance of immuni-
ty in the pathogenesis of schizophrenia 
is supported by findings of altered serum 
concentration of several proinflamma-
tory cytokines. Potvin et al (69) exam-
ined data from 62 studies, involving a 
total of 2298 schizophrenia patients and 
1858 healthy volunteers, and found con-
sistent increases in interleukin 6 (Il-6), 
soluble IL-2 receptor, and IL-1 receptor 
antagonist, and a decreased in vitro IL-2 
in schizophrenia. Il-6 is, however, also 
reduced in depression, and stress and 
weight gain are potential confounders 
(70). This highlights the care required 
in interpreting these studies, particularly 
given the infamous “pink spot” in the 
urine of patients with schizophrenia in 
the 1960s and the consistently reduced 
levels of platelet monoamine oxidase 
(MAO) in the 1980s, which were even-
tually related to smoking status (71). 
Brain imaging investigations 
There is overwhelming evidence for 
a variety of consistent abnormalities of 
brain structure and function and elec-
trophysiology in patients with schizo-
phrenia compared to healthy controls 
(72,73) (see Table 3 for examples). There 
are similar concerns as with the cogni-
tion studies about when these abnor-
malities develop. The imaging literature 
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shows, however, less evidence of het-
erogeneity across studies and somewhat 
greater evidence for specificity versus 
bipolar disorder.
Structural brain imaging
Structural magnetic resonance imag-
ing (sMRI) is relatively straightforward, 
cheap and available, and shows perhaps 
the greatest current promise as an objec-
tive diagnostic test for schizophrenia. 
The effect sizes are small, but the mea-
sures are inherently quantitative. Per-
haps the greatest single demonstration 
of the power of this approach is from 
the landmark finding that monozygotic 
twins with and without schizophrenia 
could be discriminated by simply eye-
balling their sMRI scans, and in particu-
lar the ventricles and medial temporal 
lobes, in 80% or more of the 15 pairs 
(74). Of course, twins are in short sup-
ply in clinical practice. More realistic is 
to use the evidence from what is now a 
large sMRI literature in schizophrenia, 
that there are consistent if relatively 
small reductions in whole brain, PFC 
and temporal lobe volumes (d = 0.2-0.4), 
and consistently reduced amygdala vol-
umes (d ~ 0.7) in schizophrenia (75-77). 
Moreover, the sMRI changes in schizo-
phrenia are less marked in relatives and 
others at high risk, show evidence of 
changes around the time of onset and 
are largely evident at first episode (78). 
The effect sizes are greater in schizo-
phrenia than bipolar disorder (79,80), 
and the amygdala may actually be large 
or normal in bipolar disorder (79), per-
haps particularly in younger patients. 
This merits intensive study as a possible 
discriminator, although there are techni-
cal difficulties in reliably extracting vol-
umes in such a small structure.
A number of automated support 
vector machine (SVM) analyses have 
recently been applied to sMRI data in 
schizophrenia (81). Generally, 80-90% 
of patients can be identified from their 
similarity to a group pattern for schizo-
phrenia (82-84), although these studies 
do tend to rather circularly use group 
differences to inform the group classi-
fication, and do not convincingly agree 
on the anatomical patterns of differen-
tiation. The challenges for such studies 
are to distinguish schizophrenia from 
bipolar disorder, to generate individual 
scan readings, to cross test various mod-
els on various software routines, and 
to compare them with other diagnostic 
techniques including other approaches 
to brain imaging.
functional brain imaging  
and electrophysiology
Hypofrontality
The relative underactivation of PFC 
is one of the most consistent findings 
in schizophrenia research. Zakzanis 
and Heinrichs (85) found an over-
all effect size from 21 resting positron 
emission tomography (PET) studies of 
–0.64, a 60% overlap in data distribu-
tions, and an even greater effect from 9 
activated PET studies of –1.13, a 40% 
overlap, although they did not examine 
for heterogeneity or publication bias. 
As currently reported, functional MRI 
(fMRI) studies do not lend themselves 
to the calculation of overall effect sizes, 
but hypofrontality is clearly evident in 
dorsolateral PFC on working memory 
studies (86) as it is in (left) inferior PFC 
on verbal memory tasks (87). Function-
al imaging studies and especially fMRI 
also tend to be analysed in relative rath-
er than in absolute terms, preferable for 
diagnostic evaluations. Nonetheless,  sev- 
eral classification studies have found 
that dorsolateral PFC activation on 
various tasks might distinguish schizo-
phrenia from bipolar disorder (88,89), 
and similarly high diagnostic accuracy 
(>80%) has been reported in default-
mode network activity (90) and on rest-
ing fMRI (91). However, a recent study 
found less discrimination, perhaps be- 
cause task performance differences 
clouded the picture (92). It remains to be 
seen how such an approach would cope 
with the most difficult differential, i.e. 
when those with bipolar disorder in the 
sample are experiencing active psychotic 
symptoms. 
Positron emission tomography (PET)
PET has also been used to assay neu-
rotransmitter receptors in vivo, and do-
pamine D2 receptors in particular. This 
has been a controversial field, but D2 
receptors are increased overall, with an 
effect size of 1.47 across 17 post-mortem 
and PET studies (93), including some 
medication naïve subjects. Furthermore, 
there is a very consistent literature dem-
Table 3  Large consistent effect sizes from meta-analyses of brain imaging studies in patients versus controls
Effect size 
vs. controls
Different from  
relatives
Evident at first  
episode
Specificity vs.  
affective disorder
Other issues
sMRI regional brain 
volumes
Up to 0.86, some with 
heterogeneity
(Wright et al, 76)
Yes, at least 
hippocampus  
and ventricles
Yes, at least 
hippocampus  
and ventricles
Amygdala volume may 
discriminate but may 
depend on age and 
treatment
Pattern recognition 
methods may be more 
powerful
Hypofrontality 0.64 at rest;
1.13 when active
(Zakzanis and Heinrichs, 85)
Yes Yes DLPFC activity possibly Performance level needs 
to be allowed for
Mismatch negativity 0.99
(Umbricht and Krljes, 98)
Possible Possible, but some 
possible progression
Possible -
sMRI – structural magnetic resonance imaging; DLPFC – dorsolateral prefrontal cortex
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onstrating increased pre-synaptic activity 
in the striatum, as indexed by greater am- 
phetamine-promoted dopamine release 
and greater F-DOPA uptake in schizo-
phrenia (94). A preliminary classification 
study is also encouraging (95), although 
making a distinction between schizo-
phrenia and bipolar disorder with psy-
chotic symptoms is arguably unlikely. 
Electrophysiology 
A small number of studies have pro-
vided data on the sensitivity and speci-
ficity of EEG findings in the differential 
diagnosis of schizophrenia, with very 
mixed results (96). Several measures of 
neuronal responses to stimuli, especial-
ly the P300 and P50, show large effect 
sizes versus controls, but large amounts 
of unexplained heterogeneity between 
studies (97). They also tend to show 
almost as large effects in relatives, sug-
gesting a greater loading on trait rather 
than state effects, and possibly less util-
ity for diagnosis. Mismatch negativity 
does, however, show promise in these 
regards (see Table 3) and has possible 
specificity (98). Finally, a solitary but 
impressive study has considered explor-
atory eye movements in 145 patients 
with schizophrenia from seven World 
Health Organization collaborative cen-
tres and found more than 85% sensitiv-
ity and specificity against depression 
and healthy controls (99), although a 
recent Japanese multisite study was less 
successful (100).
eArLY DiAGNosis
Diagnoses have value for communi-
cation and prognostication, but particu-
larly for planning action. Early diagno-
sis is actually akin to accurate prognos-
tication within a group as to who will 
develop the disorder of interest and 
who will not. Studies of early diagnosis 
therefore require lengthy follow-up, and 
any predictors should ideally be unam-
biguously defined and measured, and 
improve upon what can be achieved in 
current practice. Again, therefore, we 
first consider the potential role of psy-
chotic symptoms in early diagnosis.
Clinical features 
Psychotic symptoms as predictors
A range of childhood psychopatholo-
gies have been shown to predict schizo- 
phrenia. The strongest of these have 
included: self-reported psychotic symp-
toms at age 11, which increased the 
risk 16x of schizophreniform disorders 
at age 26 (101); schizophrenia spec-
trum personality disorder (PD) at mid-
teens in Israeli army conscripts males, 
increasing the risk of schizophrenia 
by 21.5 times (102); and diagnoses of 
alcohol abuse, any PD, or substance 
abuse in Swedish army conscripts aged 
18 or 19, increasing the risk of subse-
quent schizophrenia (OR 5.5, 8 and 
14, respectively) (103). These statistical 
effects are, however, insufficiently rep-
licated and too prone to high false posi-
tive rates for clinical use. 
Early diagnosis becomes more practi-
cally and ethically straightforward when 
people present as patients with pro-
dromal symptoms. Klosterkotter et al 
(104) followed 160 prodromal patients 
over a decade and found that ten “basic 
symptoms”, including subtle disturb- 
ances of mental life such as stress sen-
sitivity, had PPVs of more than 70%. 
This has yet to be replicated, however. 
The most common approach has been 
to use the ultra high risk (UHR) crite-
ria devised as a means to predict transi-
tion to psychosis in clinic attenders in 
Melbourne (105). The transition rates 
to psychosis (not just schizophrenia) 
were as high as 54% within 12 months 
at first, with PPV/NPV both more 
than 80% (106), but these figures have 
steadily fallen with time and application 
in different settings, so that transition 
rates can now be as low as 14% after 12 
months and 19% after 18 months (107). 
Several prospective cohort studies 
have followed children or adolescents at 
high genetic risk as they are offspring or 
otherwise related to patients with schizo-
phrenia. Thought disorder and negative 
symptoms, behavioural or neuromotor 
dysfunction, and attention and memory 
impairment are fairly consistent predic-
tors in these studies (108), but only two 
studies have reported data in terms of 
clinical prediction. In the New York 
High Risk Project (NYHRP), the predic-
tive power of symptoms for adulthood 
schizophreniform psychosis was not 
that high (107). In the Edinburgh High 
Risk Study (EHRS), in which the base-
line risk of transition to schizophrenia 
was 21/162 (13%), psychotic symptoms 
at interview only had a PPV of 25%, a 
schizotypal PD at interview only had a 
PPV of 29% and the strongest behav-
ioural predictor of any sort was a self-
completed questionnaire for schizotypal 
traits (the Rust Inventory of Schizotypal 
Cognitions, RISC, PPV 50%). All of 
the foregoing did, however, have NPVs 
more than 90%, and the RISC figures 
correspond to an LR+ of >5 (109). 
Risk factor prediction
These prospective cohort studies of 
young people at high genetic risk have 
also established a number of behav-
ioural abnormalities in childhood and 
adolescence that predict subsequent 
psychosis, usually with greater power 
than family history, migration, OCs 
or regular cannabis use (108). In the 
EHRS, none of those risk factors was 
a statistically significant predictor of 
schizophrenia, but several aspects of 
childhood behaviour, as elicited from 
the mothers with the Achenbach scale, 
were (109). Tarbox and Pogue-Geile 
(110) recently summarized this litera-
ture and concluded that “poor undiffer-
entiated social functioning” is a moder-
ately sensitive predictor of schizophre-
nia among children aged 7–8 in the gen-
eral population; whereas, among high 
risk children, poor social functioning 
may be quite sensitive to schizophrenia 
as early as age 5-6. However, given an 
estimated effect size (d) of about 1, and 
an OR of about 5-6, it would be mis-
taken to try to predict psychosis on this 
basis. Even with the elevated baseline 
risk of 13% in the EHRS, the sensitivity 
and specificity of such behaviours were 
too low (109).
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Physical examination and  
neuropsychological test prediction
In the NYHRP, the offspring were 
tested with neurobehavioral measures 
at 7-12 years of age and assessed in mid-
adulthood for schizophrenia-related 
diagnoses. Childhood deficits in atten-
tion, verbal memory, and gross motor 
skills identified 83%, 75%, and 58%, re-
spectively, of those with psychoses; 50% 
were identified by all three variables 
combined. Encouragingly, the three 
variables had low deficit rates in the 
offspring of two other parental groups 
and were not associated with other psy-
chiatric disorders in any group, but false 
positive rates were 18-28%, which the 
authors rightly regarded as insufficient 
evidence for antipsychotic drug prescrib-
ing (111). Michie et al (112), similarly, 
reported a false positive rate of 21% as 
unacceptably high in children assessed 
for sustained attention deficits. Worse, 
NSS were not predictors of symptoms 
or schizophrenia in EHRS (113), and 
cognitive tests were at most weak pre-
dictors (114).
Indeed, Pukrop et al (115) recently 
reviewed 32 relevant cognitive studies 
and found that investigations of neuro-
cognitive baseline assessments in high- 
risk samples are inconsistent in terms of 
the deficits found. Longitudinal studies 
tend to favour measures of processing 
speed and of verbal memory and learn-
ing as predictive of psychosis, but the 
weak predictive effects, negative studies 
and unstable performance argue against 
the usefulness of cognitive tests in early 
diagnosis, at least in isolation.
Multivariate prediction
Several studies around the world 
have now examined the predictive 
performance of combinations of symp- 
toms and other variables, with mixed 
results. Even though features like bi- 
zarre thinking and schizotypy are com-
monly replicated, they tend to do so as 
part of multivariate models which are 
dissimilar (104,105,107). The North 
American Prodrome Longitudinal Study 
(NAPLS) followed up 291 prospec-
tively identified treatment-seeking pa-
tients with prodromal syndromes cri-
teria, 35% of whom developed schizo- 
phrenia. Of 77 variables, five base-
line features contributed uniquely to 
the prediction of psychosis: a genetic 
risk for schizophrenia with recent de-
terioration in functioning (one of the 
UHR criteria), higher levels of unusual 
thought content and suspicion/para-
noia, greater social impairment, and a 
history of substance abuse (116). Pre-
diction algorithms combining 2 or 3 of 
these variables resulted in dramatic in-
creases in positive predictive power (up 
to 80%) compared with the UHR pro-
dromal criteria alone. The equally im-
pressive European Prediction Of Psy-
chosis (EPOS) study established high 
inter-rater reliability for the >60 items 
they examined and optimal prediction 
with six variables (positive symptoms, 
bizarre thinking, sleep disturbances, 
schizotypal PD, highest functioning in 
the past year, and years of education). 
This combination gives a positive like-
lihood ratio above 10 (107). It awaits 
replication, however, and did not repli-
cate the predictive power of either the 
Bonn (104) or NAPLS criteria (116).
Blood tests
In theory, the genomic biomarkers 
described above could potentially pre-
dict schizophrenia at an early stage of 
development, many years before onset. 
There are, however, only two studies 
which have taken blood before diagno-
sis, and both of these in adults rather 
than children, perhaps for practical and 
ethical reasons. In the EHRS, NRG1 
status was associated with the onset of 
psychotic symptoms (117), whereas the 
COMT Val/Met allele polymorphism 
was the only schizophrenia predictive 
blood test (Val allele present PPV 39%, 
NPV 93%; 118). This result gains partial 
support from replicated work showing 
a COMT-cannabis interaction (119), al-
though there was no such interaction in 
the EHRS. Clearly, these results require 
clarification before genotyping could be 
employed as a diagnostic marker in high 
risk groups.
Neuroimaging 
There are now a number of studies 
of people at genetic high risk or with 
prodromal symptoms who have been 
imaged at baseline and subsequently ex-
amined for transition status, some with 
follow-up imaging. Reductions of grey 
matter (GM) density in orbito-frontal 
cortex (120-122) and medial temporal 
lobe (120,122) are now clearly repli-
cated in the prodrome to schizophrenia, 
although the numbers are small. Three 
studies have taken these analyses fur-
ther into the clinical domain. Schobel 
et al (124) found that increases in hip-
pocampal CA1 cerebral blood volumes 
on contrast enhancement predicted 
subsequent psychosis with PPV 71% 
and NPV 82%. Koutsouleris et al (125) 
found overall SVM classification accu-
racies of around 90% in discriminat-
ing between at risk groups and healthy 
controls. A receiver operator charac-
teristic curve analysis of GM change in 
the inferior temporal lobes in the EHRS 
showed that these were more strongly 
predictive of schizophrenia than any 
other variable in that study, with a likeli-
hood ratio of more than 10 (126; PPV 
60%, NPV 92%). 
It would, of course, be much easi-
er and cheaper to be able to use one 
baseline scan to predict schizophre-
nia, and several groups have provided 
proof of concept studies, although the 
results are confusing. As Smieskova et 
al (127) showed in a recent systematic 
review of the literature, cross-section-
al voxel-based morphometry studies 
have replicated decreased GM in fron-
tal and cingulate cortex in the pre-psy-
chotic, yet whole brain volumes and/
or global GM volumes were consis-
tently increased. Indeed, in the EHRS, 
increased PFC folding on the first scan 
had a PPV of 67%, our strongest base-
line predictor (128). This points to a 
dramatic reduction in volumes around 
onset, which could be focus for fu-
ture investigations, and suggests that 
analysis techniques which can allow 
for baseline increases and decreases as 
well as change may have the best diag-
nostic performance. 
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PreDiCtiNG ANtiPsYChotiC 
DrUG treAtMeNt resPoNse 
Treatment response is pertinent to 
clinically relevant pathophysiology to 
the extent that available treatments ad-
dress the fundamental disease process 
or processes rather than being simply 
ameliorative in some way. We can be 
confident that antipsychotic drugs treat 
the hyperdopaminergia associated with 
positive psychotic symptoms, and even 
though it is not clear that this is the pri-
mary disease process in schizophrenia, 
there is substantial evidence that this 
represents a common pathway to acute 
delusions and hallucinations. 
Clinical predictors 
Several historical variables have been 
repeatedly associated with a good re-
sponse to antipsychotic drugs (includ-
ing symptom severity, early subjective 
and objectively rated response to the 
drug, and the duration of untreated psy-
chosis), but very few researchers have 
examined their diagnostic properties 
in prediction (129,130). Recent exam-
ples include an attempt to use baseline 
Positive and Negative Syndrome Scale 
(PANSS) scores to predict response at 
week 2, but the predictive values were 
low (131). Leucht et al (132) have 
shown that predicting non-response 
on the Brief Psychiatric Rating Scale 
(BPRS) at 4 weeks with a PPV of >80% 
was only possible if there had been ab-
solutely no improvement at all in the 
first two weeks. The prediction of remis-
sion might be improved by the inclusion 
of 4- and 6-week assessments, but the 
increase in prediction accuracy is mod-
est at best and unlikely to be clinically 
useful (133). 
The Drug Attitude Inventory is a 30 
item self report inventory which has 
good psychometric properties and di-
agnostic performance, perhaps because 
it captures elements of both an early 
subjective response and positive at-
titudes to medication (134), which are 
both associated with compliance. This 
and standardized symptom severity and 
outcome ratings might be usefully incor-
porated into routine clinical practice, at 
least to help reliably determine people’s 
attitudes to treatment and whether they 
have benefitted sufficiently to stay on a 
treatment.
Biological predictors
Biomarkers of treatment response 
do not have stiff competition, but they 
still have a long way to go. Higher anti- 
psychotic drug plasma levels and raised 
homovanillic acid (HVA) and other pe-
ripheral markers in plasma (and CSF) 
have been repeatedly related to re-
sponse, but the replicability, diagnostic 
performance and practicality of this are 
unclear (135). Further, plasma measures 
are themselves often at best indirect 
measure of cortical activity. Most po-
tential pharmacogenetic predictors of 
antipsychotic drug response have also 
fallen at the stage of reproducibility. In-
triguing findings that the COMT Val al-
lele might predict olanzapine response 
(136), that the 102-T/C 5-HT2A recep-
tor gene is associated with clozapine 
response (137), and that the DRD3 Ser 
allele is associated with poor clozapine 
response (138) all await external repli-
cation. Only the Del allele within the 
-141C Ins/Del DRD2 polymorphism 
is consistently associated with (poorer) 
antipsychotic drug response relative to 
the Ins/Ins genotype, but even this ef-
fect is too small for clinical use (139). 
The genetics of antipsychotic drug re-
sponse may therefore be as complicated 
as the genetics of schizophrenia, and the 
pharmacogenetics of psychosis might 
also require multiple gene testing.
imaging predictors of response
In sharp contrast with the diagnosis 
and early diagnosis literature reviewed 
above, structural imaging measures are 
clearly not associated with treatment 
response or resistance (140,141). There 
are, however, quite a number of studies 
showing that more abnormal computed 
tomography/sMRI appearances are as-
sociated with a generally poor prognosis 
and a bad outcome. Functional imaging 
measures show much greater promise, 
with both reduced basal ganglia metab-
olism and increased striatal D2 receptor 
occupancy being repeatedly linked to 
antipsychotic drug treatment response 
(135,142). 
There is also a strikingly consistent 
literature on the EEG and treatment 
response in schizophrenia, in which 
increased pre- and/or post-treatment al-
pha-wave EEG activity predicts response 
to antipsychotics in five out of the six 
studies we are aware of (143-148). There 
is enough replication here to justify fur-
ther studies of PET and EEG of anti- 
psychotic drug response and to begin to 
evaluate this in terms of their potential 
clinical significance. Where PET predic-
tion of response could be really useful 
is in predicting treatment resistance to 
first or second generation antipsychot-
ics and, even better, response to clozap-
ine, and perhaps also in measuring the 
response to a single test dose as a means 
to establish drug and dosage choice for 
a given patient. Those questions need, 
however, to be considered in detail by 
additional studies. The greater availabil-
ity and lesser cost of EEG make this the 
most promising potential predictive bio-
marker of antipsychotic drug response 
in psychosis for routine clinical use. 
CoNCLUsioNs AND reseArCh 
DireCtioNs
We have considered the ability of 
symptoms and signs, and a range of 
potential biomarkers, as methods of 
objectively diagnosing schizophrenia in 
established cases, in predicting transi-
tion to psychosis in people at high risk 
for clinical or genetic reasons, and in 
predicting treatment response to anti- 
psychotic medication. We have identi-
fied what we consider are the best bets 
for future research evaluation and pro-
vided some pointers about how these 
studies should be conducted and re-
ported (Table 4). Some will say this is all 
premature. It would certainly be foolish 
to think that we are ready to employ 
these measures in clinical practice, but 
we think that it is long overdue to start 
considering the variables and methods 
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which can take us towards objective 
diagnostic testing in psychiatry, and to 
report data in terms of predictive values 
and likelihood ratios, or at least in such 
a way as these can be calculated.
The current “gold standard” for the 
diagnosis of schizophrenia allows reli-
able diagnoses to be made and commu-
nicated, and has some predictive validity 
in terms of denoting a poor prognosis 
in most patients. It is frequently stated 
that these criteria lack biological valid-
ity, yet there is no doubt that they have 
allowed aspects of the pathophysiology 
of schizophrenia and other psychoses 
to be elucidated. The symptomatic and 
biological boundaries between schizo-
phrenia and bipolar disorder may not be 
discrete (149,150), but where there have 
been direct comparisons we have been 
able to highlight some promising leads. 
We fully acknowledge, and indeed it is a 
key motivator to writing this article, that 
our diagnostic gold standard is tarnished 
and can be variably applied. Replacing 
this with another set of subjective criteria 
would, however, be comparable to rear-
ranging deck chairs on the Titanic. We 
should aim much higher as a profession 
– towards objective, etiological and/or 
pathophysiological measures. We have 
been overcautious in pursuing this agen-
da in psychiatry, as a medical discipline, 
perhaps in part because of the hype and 
then failure of the dexamethasone sup-
pression test in depression (151). 
We regard the diagnosis section of 
this paper as the most important part, 
because a suitable patient population is 
available to all clinicians, a diagnosis is 
usually already made, and this is there-
fore where an objective approach would 
have most impact. Epidemiological risk 
factors need to be formally evaluated in 
terms of how much they should right-
fully increase diagnostic suspicion (or 
likelihood), especially when considered 
with other factors, and as potential caus-
al specifiers for psychosis. We also need 
to determine if there are any objective, 
reliable “soft signs”, and how these and 
brief cognitive tests of intellectual de-
cline from premorbid function may per-
form in clinical practice in terms of their 
practicality and utility in patients with 
acute psychosis. Meanwhile, geneticists 
need to establish how we will know a 
causal gene when we see one, and how 
we will manage the patients carrying 
it. Imaging “biomarkers” perhaps have 
most promise for diagnostics, but the 
imaging community needs to develop 
quantitative techniques that can be ap-
plied to individual patients and apply 
these to the critical distinction between 
schizophrenia and bipolar disorder with 
psychotic symptoms. Amygdala volumes 
may require standardization by age and 
account for medication if they are to be 
a distinguishing feature, while dorsolat-
eral PFC activation patterns will require 
standardization by performance and 
perhaps IQ, although resting state func-
tional imaging studies may circumvent 
this. 
Making diagnoses at earlier stages in 
the illness and therapeutic response pre-
dictions are not lesser priorities but do 
seem less practical propositions. Risk 
factors are all too rare and insufficiently 
powerful predictors of psychosis to be 
of great diagnostic value in essentially 
healthy people, quite apart from the 
ethical issues inherent in predictive ge-
netic testing and possible prescription of 
unproven treatments for large numbers 
of people years before a few become ill. 
Early diagnosis becomes more practical 
and ethically straightforward nearer to 
the time of onset, when the severity of 
symptoms, thought disruption, schizo-
typy, cannabis use and brain imaging 
again look to have promise. It is, how-
ever, at least debatable to what extent 
a predictive test for schizophrenia, or 
indeed of antipsychotic drug response, 
would be used, even if predictors were 
strong, given the limited resources for 
early intervention services, the restricted 
choice of treatments currently available, 
and the lack of availability of imaging 
and genetic technologies in most clini-
cal settings even in so-called developed 
nations.
Even more important than the specif-
ics at this stage is the general approach. 
The one critical aspect of diagnostic stud-
ies that is often forgotten is the necessity 
of a reliable test of the proposed diag-
nostic aid in a second independent and 
preferably similarly large cohort, also 
conducted blind to diagnosis. As fitted 
models of multiple variables always per-
form in an “optimistic manner”, or are 
“over-fitted” on the model-development 
data, cross-validation in an independent 
sample is needed to control for tailor-
made modelling. We are not aware of 
any examples of this having been done 
in a truly independent cohort for any of 
the findings we have described. This re-
quires large scale clinical research stud-
ies, which may require support from a 
variety of informatics approaches, in-
cluding computational models of the 
brain/mind, normative and illness data-
bases for comparisons, multivariate pre-
diction algorithms and so on (152,153). 
Multilevel models including neurobio-
logical, sociobiographical, and envi-
ronmental variables may increase pre-
dictive accuracy, but each additional 
domain also brings potential variations 
according to study setting, levels of ex-
Table 4  Summary of research findings
 – Particular psychotic symptoms are not in themselves strong associates or predictors of schizophrenia,  
   because of their relative rarity, the difficulties in reliably eliciting them and their lack of specificity.
 – Developmental abnormalities (social, sensorimotor, intellectual), whether elicited in the history  
   or on examination, merit formal evaluation as potential diagnostic aids, but these may simply be  
   trait markers.
 – A number of genetic markers of schizophrenia have been identified, but the impact of such testing  
   in clinical practice needs to be established.
 –  Of currently available technological approaches, structural brain imaging looks most promising  
   as a diagnostic aid, and in the early detection of psychosis (at least within high risk populations).
 – Functional imaging should be more sensitive, but is more expensive and technically demanding,  
   and may have particular value in differential diagnosis and response prediction. 
 –  Imaging and other approaches should be further improved by genotyping and/or other biomarkers  
   as they become available – although with each additional test false negatives tend to become more  
   of a problem.
 – Ideally, clinically significant test results should be examined in clinical trials to establish whether the    
   time and expense involved impacts favourably on patient outcome.
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posure and inter-rater reliability, as well 
increasing the risk of false negatives. 
The biggest stumbling block clinical 
researchers may face in trying to set up 
such studies and change diagnostic pra- 
ctice in psychiatry is concern about how 
certain one needs to be of an etiological 
risk factor or pathophysiological mech-
anism and its specificity before it can 
be used as a diagnostic aid or test. This 
is, of course, a legitimate question, but 
it misses the key point – at least from a 
clinical perspective – of whether or not 
the presence of a marker in an individ-
ual takes it beyond a threshold where 
diagnosis or some management strategy 
which follows from it is likely to be of 
benefit. Establishing the requisite mea-
sures and thresholds will require formal 
studies in their own right. Clinicians 
will need to participate in large simple 
studies to identify the most clinically 
useful symptoms and signs and tests. 
This is how medicine works and, with 
additional study, advances. It is the way 
psychiatry needs to travel if we are to 
start to use objective indices to inform 
psychiatric classification and practice. 
The future of psychiatry as a medical 
discipline may depend on it.
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